We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+29.17%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$836M
AUM Growth
+$210M
Cap. Flow
+$82.3M
Cap. Flow %
9.85%
Top 10 Hldgs %
42.54%
Holding
96
New
9
Increased
7
Reduced
5
Closed
14

Top Buys

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$15.2M
2
CLLS
Cellectis
CLLS
+$13.9M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$12.6M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.74M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$9.21M

Top Sells

Rank Stock Value
1
RGLS
Regulus Therapeutics
RGLS
+$7.23M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$5.84M
3
ARRY
Array Biopharma Inc
ARRY
+$3.88M
4
CRIS icon
Curis
CRIS
+$3.59M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$3.17M

Sector Composition

Rank Sector Weight
1 Healthcare 91.58%
2 Miscellaneous 8.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
76
DELISTED
Molecular Templates, Inc.
MTEM
$480K 0.06%
+6,061
New +$2.99M
CLRB icon
77
Cellectar Biosciences
CLRB
$22.3M
$390K 0.05%
18
– –
AGTC
78
DELISTED
Applied Genetic Technologies Corporation
AGTC
$349K 0.04%
17,110
– –
ADAP
79
DELISTED
Adaptimmune Therapeutics
ADAP
$302K 0.04%
25,000
– –
RGLS
80
DELISTED
Regulus Therapeutics
RGLS
$267K 0.03%
255
-7,216
-97% -$7.23M
AKBA icon
81
Akebia Therapeutics
AKBA
$258M
– –
-100,300
Closed -$969K
AKTX
82
Akari Therapeutics
AKTX
$20M
– –
-36
Closed -$687K
DARE icon
83
Dare Bioscience
DARE
$14.6M
– –
-4,595
Closed -$2.02M
GALT icon
84
Galectin Therapeutics
GALT
$374M
– –
-286,200
Closed -$670K
HRTX icon
85
CALL
Heron Therapeutics
HRTX
$60.4M
– –
-5,000
Closed -$100K
KPTI icon
86
Karyopharm Therapeutics
KPTI
$37.7M
– –
-20,066
Closed -$3.17M
SCYX icon
87
SCYNEXIS
SCYX
$41.6M
– –
-1,242
Closed -$723K
SGMO
88
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-361,000
Closed -$2.04M
TLPH icon
89
Talphera
TLPH
$61.8M
– –
-42,500
Closed -$2.59M
ARAV
90
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-28,333
Closed -$1.96M
DRNA
91
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-245,000
Closed -$2.01M
KIN
92
DELISTED
Kindred Biosciences, Inc.
KIN
– –
-328,497
Closed -$1.71M
ARRY
93
DELISTED
Array Biopharma Inc
ARRY
– –
-850,000
Closed -$3.88M
1 2 3
4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q4 2015 Portfolio in Review

As of Q4 2015, Cormorant Asset Management held 96 positions worth $836M, up 34% from $626M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Cormorant Asset Management deployed $82.3M of net new capital in Q4 2015, opening 9 new positions and adding to 7 existing holdings. Its largest new stake was MacroGenics: 500,000 shares worth $15.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Regulus Therapeutics, an estimated $7.23M trimmed.

  • Cormorant Asset Management's largest Q4 2015 buy was MacroGenics: 500,000 shares worth $15.5M.
  • Cormorant Asset Management added most to Cellectis in Q4 2015, an estimated $13.9M increase.
  • Cormorant Asset Management's biggest Q4 2015 reduction was Regulus Therapeutics, cutting an estimated $7.23M.
  • Cormorant Asset Management fully exited Array Biopharma Inc in Q4 2015, selling an estimated $3.88M.
  • Cormorant Asset Management's ten largest holdings make up 43% of its $836M portfolio in Q4 2015.
  • Cormorant Asset Management opened 9 new positions and closed 14 in Q4 2015.
  • Cormorant Asset Management's portfolio value rose 34% quarter-over-quarter to $836M.

Based on Cormorant Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.